secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2025-12-10T23:59:59+00:00
Accession:  0001828185-25-000075
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio Phase 1 AVALON trial of VTP-1000 shows safety, dose-dependent effect in celiac disease
--------------------------------------------------------------------------------

- VTP-1000 well-tolerated in SAD portion; no treatment-related serious adverse events.
- Dose-dependent pharmacological effect observed across 18 patients in three cohorts.
- MAD portion with gluten challenge ongoing; data expected in second half of 2026.
- VTP-1000 uses SNAP-TI platform to co-deliver gluten antigens and rapamycin, promoting immune tolerance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818525000075/0001828185-25-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818525000075/brns-20251210.htm
  HTML page:      https://secwatch.observer/filing/0001828185-25-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer